CinDome Pharma

CinDome Pharma is a Cincinnati company in the CinRx Pharma portfolio developing deudomperidone (CIN-102), a deuterated, newly formulated version of domperidone that the company says is designed for reduced heart rhythm (QT) risk. It completed enrollment in envisionGI, a Phase 2 trial that enrolled 416 adults with idiopathic gastroparesis, in March 2026, after an earlier Phase 2 trial in diabetic gastroparesis.

CinDome Pharma has active programs across 1 rare disease: Gastroparesis. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.

CinDome Pharma is a diversified pharmaceutical company headquartered in Cincinnati, United States. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 1 active rare disease program including Gastroparesis. Many of its rare disease treatments hold orphan drug designations from the FDA.

The clinical trials section on this page shows active and recruiting rare disease trials sponsored by CinDome Pharma, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.

To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.